These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 31623231)

  • 1. The CD73/Ado System-A New Player in RT Induced Adverse Late Effects.
    de Leve S; Wirsdörfer F; Jendrossek V
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
    de Leve S; Wirsdörfer F; Jendrossek V
    Front Immunol; 2019; 10():698. PubMed ID: 31024543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.
    Meyer AV; Klein D; de Leve S; Szymonowicz K; Stuschke M; Robson SC; Jendrossek V; Wirsdörfer F
    Front Oncol; 2020; 10():554883. PubMed ID: 33194619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.
    Vaupel P; Multhoff G
    Strahlenther Onkol; 2016 May; 192(5):279-87. PubMed ID: 26961686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
    Bao X; Xie L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
    Wirsdörfer F; de Leve S; Jendrossek V
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling DNA damage-induced pneumopathy in mice: insight from danger signaling cascades.
    Wirsdörfer F; Jendrossek V
    Radiat Oncol; 2017 Aug; 12(1):142. PubMed ID: 28836991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives.
    de Andrade Mello P; Coutinho-Silva R; Savio LEB
    Front Immunol; 2017; 8():1526. PubMed ID: 29184552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.
    Montalbán Del Barrio I; Penski C; Schlahsa L; Stein RG; Diessner J; Wöckel A; Dietl J; Lutz MB; Mittelbronn M; Wischhusen J; Häusler SFM
    J Immunother Cancer; 2016; 4():49. PubMed ID: 27532024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy.
    Guan H; Zhou Z; Hou X; Zhang F; Zhao J; Hu K
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):35-50. PubMed ID: 35538049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity.
    Silva-Vilches C; Ring S; Mahnke K
    Front Immunol; 2018; 9():2581. PubMed ID: 30473700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD39/CD73/A2AR pathway and cancer immunotherapy.
    Xia C; Yin S; To KKW; Fu L
    Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors.
    Chambers AM; Lupo KB; Wang J; Cao J; Utturkar S; Lanman N; Bernal-Crespo V; Jalal S; Pine SR; Torregrosa-Allen S; Elzey BD; Matosevic S
    Elife; 2022 Jul; 11():. PubMed ID: 35815945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the CD73-adenosine axis in immuno-oncology.
    Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
    Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL
    Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD73, Tumor Plasticity and Immune Evasion in Solid Cancers.
    Yang H; Yao F; Davis PF; Tan ST; Hall SRR
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33430239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
    Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
    Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme activity of circulating CD73 in human serum.
    Morello S; Turiello R; Madonna G; Pinto A; Ascierto PA; Capone M
    Methods Enzymol; 2019; 629():257-267. PubMed ID: 31727244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine.
    Passarelli A; Tucci M; Mannavola F; Felici C; Silvestris F
    Tumour Biol; 2019 Apr; 42(4):1010428319837138. PubMed ID: 30957676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.